Development of immunotoxins for potential clinical use in Hodgkin's disease.
During the last decade, immunotoxins (ITs) consisting of a cell-binding moiety and a potent toxin were developed as a new class of biological anti-tumor agents. Hodgkin's disease has shown to be one of the best targets for immunotoxins, as lymphocyte activation markers such as CD25 and CD30 are expressed on Hodgkin and Reed-Sternberg (H-RS)-cells in large numbers. Several immunotoxins against these antigens, which are expressed physiologically only on a small subset of activated hematopoietic cells have demonstrated potent anti-tumor effects both, in vitro and in animal models. Here we summarize the experimental and recent clinical data of using ITs in Hodgkin's disease.
Barth
S
S
Klinik I für Innere Medizin, Universität zu Köln, Germany.
Schnell
R
R
Diehl
V
V
Engert
A
A
D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*
D000922:Immunotoxins